Alexander R. Gottschalk, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
gottschalk_alexander

Assistant Professor, Department of Radiation Oncology, UCSF

Phone: (415) 353-9807 (appts)
Box 1708, UCSF
San Francisco, CA 94143-1708

View on UCSF Profiles


Additional Websites


Education

University of Chicago, Chicago, IL, B.A., 1988, Chemistry
University of Chicago, Chicago, IL, Ph.D., 1994, Pathology
University of Chicago, Chicago, IL, M.D., 1996, Medicine
Kaiser Permanente Medical Center, 1996-1997, Internship Medicine
University of California, San Francisco, 1997-2001, Resident Radiation Oncology


Professional Experience

  • 2001-2008
    Assistant Professor, Department of Radiation Oncology, University of California, San Francisco
  • 2007-2008
    Interim Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco
  • 2008-present
    Associate Professor, Department of Radiation Oncology, University of California, San Francisco
  • 2008-present
    Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco

Honors & Awards

  • 1988-96
    NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
  • 1998-99
    NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
  • 2000
    RSNA Research and Education Foundation Roentgen Resident/Fellow Research Award
  • 2001-02
    Clinical Investigator Research Program Recipient, University of California San Francisco
  • 2002
    Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD,
  • 2002-03
    UCSF Prostate Cancer SPORE Developmental Research Program Award
  • 2003-05
    RSNA Research Scholar Award
  • 2003-05
    American Society of Therapeutic Radiation and Oncology Junior Faculty Award

Selected Publications

  1. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed
  2. Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
    View on PubMed
  3. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Response to drs rogers, hayes, and demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
    View on PubMed
  4. Gottschalk A. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: An analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26]. Urol Oncol. 2014 Apr; 32(3):374.
    View on PubMed
  5. Gottschalk A. Commentary on "Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer." Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Harvard Radiation Oncology Program, Boston, MA.: Cancer 2013;119(9):1729-35. doi: 10.1002/cncr.27956. [Epub 2013 Feb 22]. Urol Oncol. 2014 Apr; 32(3):373-4.
    View on PubMed
  6. Gottschalk A. Commentary on "A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma." Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia.: BJU Int 2012;110(11 Pt B):E737-43. doi: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29]. Urol Oncol. 2014 Apr; 32(3):374-5.
    View on PubMed
  7. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
    View on PubMed
  8. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9(1):42.
    View on PubMed
  9. Gottschalk A. Commentary on "Secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: Incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13]. Urol Oncol. 2014 Feb; 32(2):209.
    View on PubMed
  10. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
    View on PubMed
  11. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
    View on PubMed
  12. Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys. 2013; 14(5):162-72.
    View on PubMed
  13. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
    View on PubMed
  14. Eberhardt SC, Carter S, Casalino DD, Merrick G, Frank SJ, Gottschalk AR, Leyendecker JR, Nguyen PL, Oto A, Porter C, Remer EM, Rosenthal SA. ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance. J Am Coll Radiol. 2013 Feb; 10(2):83-92.
    View on PubMed
  15. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206.
    View on PubMed
  16. Gottschalk A, Brodner G, Van Aken HK, Ellger B, Althaus S, Schulze HJ. Can regional anaesthesia for lymph-node dissection improve the prognosis in malignant melanoma? Br J Anaesth. 2012 Aug; 109(2):253-9.
    View on PubMed
  17. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):370-7.
    View on PubMed
  18. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75.
    View on PubMed
  19. Vidal-Gadea A, Topper S, Young L, Crisp A, Kressin L, Elbel E, Maples T, Brauner M, Erbguth K, Axelrod A, Gottschalk A, Siegel D, Pierce-Shimomura JT. Caenorhabditis elegans selects distinct crawling and swimming gaits via dopamine and serotonin. Proc Natl Acad Sci U S A. 2011 Oct 18; 108(42):17504-9.
    View on PubMed
  20. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):228-34.
    View on PubMed

Go to UCSF Profiles, powered by CTSI